Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M250Revenue $M6.3Net Margin (%)-569.4Z-Score-46.2
Enterprise Value $M278EPS $-0.2Operating Margin %-440.4F-Score4
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-569.4Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0.8Cash flow > EarningsY
Price/Sales39.45-y EBITDA Growth Rate %31.1Current Ratio1.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-141.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M150ROI % (ttm)-168.4Gross Margin Increase y-yY

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

NAVB is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GOLDBERG MICHAEL MDirector 2014-11-14Buy100,000$1.0854.63view
FORD BRENDAN ADirector 2014-11-10Buy10,000$1.0362.14view
Nordlicht Mark10% Owner 2014-09-02Sell60,000$1.3622.79view
Regan William J.SVP-Global Reg Affairs&Quality 2014-05-12Buy5,000$1.4316.78view
PYKETT MARK JEROMECEO 2014-05-09Buy10,000$1.3424.63view
Cope Frederick OSVP 2014-03-10Sell15,000$1.96-14.8view
LARSON BRENT LEVP, CFO, Treas & Secy 2014-03-10Sell41,500$1.96-14.8view
PYKETT MARK JEROMECEO 2014-03-10Sell120,000$1.96-14.8view
FORD BRENDAN ADirector 2013-11-08Buy20,000$1.4515.17view
LARSON BRENT LEVP, CFO, Treas & Secy 2013-11-08Buy5,000$1.3920.14view

Press Releases about NAVB :

    Quarterly/Annual Reports about NAVB:

    News about NAVB:

    Articles On GuruFocus.com
    Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
    comment on NAVB Mar 16 2013 

    More From Other Websites
    Navidea Biopharmaceuticals Announces Presentation of Lymphoseek® Data at Society of Surgical... Mar 25 2015
    Navidea Biopharmaceuticals Announces Presentation of Lymphoseek® Data at Society of Surgical... Mar 25 2015
    Macrophage Therapeutics to Expand Efforts Into CNS Diseases Mar 20 2015
    Macrophage Therapeutics to Expand Efforts Into CNS Diseases Mar 20 2015
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Mar 19 2015
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 16 2015
    Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Executes Securities Purchase... Mar 13 2015
    Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Executes Securities Purchase... Mar 13 2015
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 11 2015
    CLARIFICATION of Navidea Announces Fourth Quarter and Full Year 2014 Results Mar 05 2015
    CLARIFICATION of Navidea Announces Fourth Quarter and Full Year 2014 Results Mar 05 2015
    Navidea Announces Fourth Quarter and Full Year 2014 Results Mar 05 2015
    Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2... Mar 05 2015
    Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2... Mar 05 2015
    Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Appoints Leading Experts to... Feb 27 2015
    Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Appoints Leading Experts to... Feb 27 2015
    Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March... Feb 26 2015
    Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March... Feb 26 2015
    Lymphoseek® Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck... Feb 18 2015
    Lymphoseek® Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck... Feb 18 2015
    Lymphoseek® Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck... Feb 17 2015
    Lymphoseek® Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck... Feb 17 2015
    Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News Feb 09 2015
    Navidea Reports Preliminary 2014 Revenue; Provides Update on New Commercial Strategy Feb 09 2015
    Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9 Feb 02 2015
    Lymphoseek® Performance vs. Sulfur Colloid in Breast Cancer Patients Published in Annals of... Jan 29 2015
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 26 2015
    Navidea’s Macrophage Therapeutics Unit Announces Plan for $2.5 Million Financing Jan 21 2015
    Navidea Biopharmaceuticals to Present at Biotech Showcase 2015 Jan 06 2015
    Navidea Biopharmaceuticals to Present at Biotech Showcase 2015 Jan 06 2015
    Navidea Strengthens Leadership Team to Accelerate Lymphoseek® Growth Jan 05 2015
    Navidea Strengthens Leadership Team to Accelerate Lymphoseek® Growth Jan 05 2015
    Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept™ in... Dec 12 2014
    Navidea Forms Macrophage Therapeutics Business Unit to Explore Therapeutic Applications of... Dec 10 2014
    Navidea Biopharmaceuticals to Present at the 2014 LD Micro Conference Nov 25 2014
    European Commission Approves Navidea’s Sentinel Lymph Node Detection Agent Lymphoseek® Nov 20 2014
    Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status; Platinum... Nov 11 2014
    Navidea Announces Third Quarter 2014 Financial Results Nov 06 2014
    Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European... Oct 30 2014
    Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European... Oct 30 2014
    Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014 Oct 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK